Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07363525

Michigan Initial Experience Using Tigertriever for Thrombectomy

The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Blood Clot Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Embolism and Thrombosis Ischemic Stroke Nervous System Diseases Stroke Thrombectomy Thrombosis Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

You have been asked to take part in a research study because you have recently been admitted for large vessel occlusion (LVO) and are being treated by Tigertriever.

The treatment is a standard of care (SOC), and if you agree to take part in this study, your participation will include an additional study visit after 3 months. Your study visit will take place at Henry Ford Hospital Neurology or respective collaborator.

For some research studies, such as the one you are being asked to join, it is important that you do not learn the results of certain tests. Whether you intend it or not, sometimes learning this information may make you change your actions and behaviors in ways that could impact the outcome of the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
  • Tigertriever was used as the first line treatment in the target vessel.
  • A signed informed consent.
  • Age ≥ 18.

Exclusion criteria

-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.

  • pre-stroke disability (pre-stroke mRS ≥ 2).

Treatment and study plan

Mechanical thrombectomy

Procedure

You will be asked to provide medical history, take neurological exams in the form of questionnaires, and provide imaging data.

Primary outcomes

  1. Modified Rankin Scale

    Time frame: From enrollment to 90 days post treatment

    Percentage of participants with a modified Rankin Scale (mRS) score ≤2

  2. Primary Effectiveness Endpoint

    Time frame: By the end of the thrombectomy procdure.

    Percentage of participants with a mTICI Score ≥IIb

  3. Primary Effectiveness Endpoint - mTICI

    Time frame: From time of event to after the first thrombectomy pass.

    Percentage of participants with a mTICI Score ≥IIb after the first pass

Study contacts

Contact information is provided by the study sponsor or research team.

Alex Chebl, MD

CONTACT

[email protected]

313-916-2644

Kelly Tundo, RN

CONTACT

[email protected]

313-916-1102

Sponsors and collaborators

Lead sponsor

Henry Ford Health System

Other

Registry information

Acronym: MIGHTY

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jan 23, 2026
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.